London Daily

Focus on the big picture.
Wednesday, Oct 01, 2025

Hong Kong not alone in finding faulty BioNTech vaccine packaging, experts say

Hong Kong not alone in finding faulty BioNTech vaccine packaging, experts say

In countries such as Britain and the United States, there have been reports of a handful of similar cases of defective packaging in BioNTech vaccines, Society of Hospital Pharmacists chief says.

The level of defects in the BioNTech Covid-19 vaccine in Hong Kong is not particularly high, according to local experts, who point out countries overseas have not suspended their inoculation programmes despite packaging faults also being found in a small number of products.

The debate on how defective packaging might compromise vaccine safety continued to rage among the scientific community on Thursday after the Hong Kong government suspended the use of BioNTech jabs because of faulty bottles.

A BioNTech spokeswoman on Thursday said the affected batch – numbered 210102 – was only delivered to Hong Kong and Macau, and a probe had been launched into the cause of the defects.

Asked whether the company knew of any defective packaging in other batches, she said: “No other region has been supplied with doses from this batch. No other batches shipped to other regions are affected by this investigation.”

The batch was supplied by Fosun Pharma, which has the rights to distribute the German-made vaccine in mainland China, Hong Kong, Macau and Taiwan.

In countries such as Britain and the United States, pharmacists had reported a handful of similar cases of defective packaging in BioNTech vaccines, but they did not halt their vaccination schemes, according to William Chui Chun-ming, president of the Society of Hospital Pharmacists of Hong Kong.

“Defects have been reported in other places from time to time, although the number of cases is not as high as in Hong Kong,” he said.

Chui noted that faulty packaging, such as loose metal rings, also occurred occasionally in vials for medicines such as antibiotics.

He believed BioNTech had not asked Britain or the US to halt vaccinations because not enough cases were reported.

“The number of product complaints acts as a signal to alert the company that there might be problems occurring in their vaccine,” he said. “Suspension of the batch will be triggered when it reaches a certain number, which is decided by the company internally.”

Chui said although the vaccines could be manufactured at different plants, that would not be the reason for the spike in the defect rate in Hong Kong compared with elsewhere.

“The operation guideline across different manufacturing plants is the same. The production plant is standardised to control the quality of its vaccine, otherwise, it would be very dangerous and affect the company’s reputation,” he said.

Government pandemic adviser Professor David Hui Shu-cheong said he was also told of faulty BioNTech bottles in Britain, but the number of cases was not high enough to call for a temporary suspension of those jabs.

Hong Kong officials said more than 50 defects including cracks, air pressure issues resulting in leaks, tilted or loose vial seals, as well as stains or marks outside the glass containers were reported, but all potentially spoiled vials had been disposed of.

The BioNTech vaccine arrived in Hong Kong last month and was rolled out on March 6.


Of the 585,000 doses in batch 210102, a quarter, or 151,300, had been used in Hong Kong. The city’s supply of batch 210104 was not yet in use and all of its 758,000 doses were in storage.

Chui said the spoilage ratio was low – 57 out of the 150,000 doses used in the city, giving a rate of less than 0.1 per cent. Still, he still felt it showed the pharmaceutical company had failed to act as a gatekeeper over the quality of its products.

Hui agreed the defect ratio was not high, as the BioNTech vaccine was stored in a glass bottle because it required dilution. He added that such packaging defects were less likely to happen with Sinovac and Moderna jabs as they were stored in a prefilled syringe and did not require dilution.

Authorities in Hong Kong and Macau stressed that there was no evidence to suggest the doses in question posed any health risk, adding that the faulty bottles were not administered to jab recipients.

Meanwhile, all of the 100,425 BioNTech shots procured by Macau were from batch 210102. As of Tuesday, a total of 6,215 doses, or 6.2 per cent, were administered, the health bureau said on Wednesday.

Asked whether Macau had reported similar packaging defects, a bureau spokesman said they did not have additional information to provide.

Two vaccines have been approved for emergency use in Hong Kong so far – CoronaVac produced by Beijing-based Sinovac Biotech and the jab known by the brand name Comirnaty jointly developed by Germany’s BioNTech and US-based Pfizer.

Shanghai-based Fosun is BioNTech’s partner in the development and distribution of Comirnaty jabs in Greater China. Pfizer is BioNTech’s partner for vaccines elsewhere in the world.

Hui revealed Fosun had already suggested to the Hong Kong government an alternative supplier from Germany to manufacture the city’s BioNTech vaccine.

Hong Kong launched BioNTech jabs as part of its vaccination drive, which began late last month, on March 6.

Dr Siddharth Sridhar, a clinical virologist at the University of Hong Kong, said defects in vaccine packages were uncommon.

“I would expect that a certain proportion of vials become damaged at some point during manufacture, transport or thawing no matter where the vaccine is used. If the company can come back and say there is nothing wrong with the process and [quality control] checks out, we can hopefully resume vaccinations with BioNTech,” he said.


Chui, the pharmacist, also criticised BioNTech for its follow-up action on the suspension.

“In normal practice, a responsible pharmacy should alert the local government in advance before issuing their announcement … They should also help with transferring other batches or certain amounts of vaccines to Hong Kong,” he said.

Chui suggested the company set up a production line solely for the manufacturing of vaccines supplied to the city and Macau.

Professor Ian Wong Chi-kei, head of HKU’s department of pharmacology and pharmacy, said the Department of Health’s Drug Office had a system in place to report defective pharmaceutical products, including vaccines.

That information was then relayed to the Hospital Authority and other health care providers to recall the faulty products.

“In pharmaceutical production, there are very comprehensive quality control procedures in order to ensure the high quality of medicines and vaccines. However, in some rare occasions, defective batches are detected, not just for vaccines but also for other medicines,” he said.

Newsletter

Related Articles

0:00
0:00
Close
Trump Administration Launches “TrumpRx” Plan to Enable Direct Drug Sales at Deep Discounts
Trump Announces Intention to Impose 100 Percent Tariff on Foreign-Made Films
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Singapore and Hong Kong Vie to Dominate Asia’s Rising Gold Trade
Trump Organization Teams with Saudi Developer on $1 Billion Trump Plaza in Jeddah
Manhattan Sees Surge in Office-to-Housing Conversions, Highest Since 2008
Switzerland and U.S. Issue Joint Assurance Against Currency Manipulation
Electronic Arts to Be Taken Private in Historic $55 Billion Buyout
Thomas Jacob Sanford Named as Suspect in Deadly Michigan Church Shooting and Arson
Russian Research Vessel 'Yantar' Tracked Mapping Europe’s Subsea Cables, Raising Security Alarms
New York Man Arrested After On-Air Confession to 2017 Parents’ Murders
U.S. Defense Chief Orders Sudden Summit of Hundreds of Generals and Admirals
Global Cruise Industry Posts Dramatic Comeback with 34.6 Million Passengers in 2024
Trump Claims FBI Planted 274 Agents at Capitol Riot, Citing Unverified Reports
India: Internet Suspended in Bareilly Amid Communal Clashes Between Muslims and Hindus
Supreme Court Extends Freeze on Nearly $5 Billion in U.S. Foreign Aid at Trump’s Request
Archaeologists Recover Statues and Temples from 2,000-Year-Old Sunken City off Alexandria
China Deploys 2,000 Workers to Spain to Build Major EV Battery Factory, Raising European Dependence
Speed Takes Over: How Drive-Through Coffee Chains Are Rewriting U.S. Coffee Culture
U.S. Demands Brussels Scrutinize Digital Rules to Prevent Bias Against American Tech
Ringo Starr Champions Enduring Beatles Legacy While Debuting Las Vegas Art Show
Private Equity’s Fundraising Surge Triggers Concern of European Market Shake-Out
Colombian President Petro Vows to Mobilize Volunteers for Gaza and Joins List of Fighters
FBI Removes Agents Who Kneeled at 2020 Protest, Citing Breach of Professional Conduct
Trump Alleges ‘Triple Sabotage’ at United Nations After Escalator and Teleprompter Failures
Shock in France: 5 Years in Prison for Former President Nicolas Sarkozy
Tokyo’s Jimbōchō Named World’s Coolest Neighbourhood for 2025
European Officials Fear Trump May Shift Blame for Ukraine War onto EU
BNP Paribas Abandons Ban on 'Controversial Weapons' Financing Amid Europe’s Defence Push
Typhoon Ragasa Leaves Trail of Destruction Across East Asia Before Making Landfall in China
The Personality Rights Challenge in India’s AI Era
Big Banks Rebuild in Hong Kong as Deal Volume Surges
Italy Considers Freezing Retirement Age at 67 to Avert Scheduled Hike
Italian City to Impose Tax on Visiting Dogs Starting in 2026
Arnault Denounces Proposed Wealth Tax as Threat to French Economy
Study Finds No Safe Level of Alcohol for Dementia Risk
Denmark Investigates Drone Incursion, Does Not Rule Out Russian Involvement
Lilly CEO Warns UK Is ‘Worst Country in Europe’ for Drug Prices, Pulls Back Investment
Nigel Farage Emerges as Central Force in British Politics with Reform UK Surge
Disney Reinstates ‘Jimmy Kimmel Live!’ after Six-Day Suspension over Charlie Kirk Comments
U.S. Prosecutors Move to Break Up Google’s Advertising Monopoly
Nvidia Pledges Up to $100 Billion Investment in OpenAI to Power Massive AI Data Center Build-Out
U.S. Signals ‘Large and Forceful’ Support for Argentina Amid Market Turmoil
Nvidia and Abu Dhabi’s TII Launch First AI-&-Robotics Lab in the Middle East
Vietnam Faces Up to $25 Billion Export Loss as U.S. Tariffs Bite
Europe Signals Stronger Support for Taiwan at Major Taipei Defence Show
Indonesia Court Upholds Military Law Amid Concerns Over Expanded Civilian Role
Larry Ellison, Michael Dell and Rupert Murdoch Join Trump-Backed Bid to Take Over TikTok
Trump and Musk Reunite Publicly for First Time Since Fallout at Kirk Memorial
Vietnam Closes 86 Million Untouched Bank Accounts Over Biometric ID Rules
×